For years, injectable treatments have dominated medicated weight loss – effective, clinically proven, but not without their inconveniences.
That is about to change.
On 11 June 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the Wegovy pill.
This makes the United Kingdom only the third country in the world, after the United States and the United Arab Emirates, to licence an oral GLP-1 receptor agonist for weight management.
It is a landmark moment, and at McMinn’s Pharmacy, we are preparing to stock the pills as soon as they come to market.
Here is what you need to know.
What Is the Wegovy Pill?
The Wegovy pill contains semaglutide – the same active ingredient found in the Wegovy injection – but in tablet form.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist.
It works by mimicking a gut hormone that regulates appetite and blood sugar, reducing hunger and helping patients feel fuller for longer.
The MHRA has approved the pill as an adjunct to a reduced-calorie diet and increased physical activity for adults living with obesity (BMI ≥30 kg/m²), or for those who are overweight (BMI ≥27 kg/m²) with at least one weight-related condition.
These conditions include high blood pressure, type 2 diabetes, or sleep apnoea.
How Effective Is The Wegovy Pill?
In clinical trials, adults with obesity taking the 25 mg semaglutide tablet achieved an average weight loss of approximately 13.6% over 64 weeks.
Those in the placebo group achieved just 2.4% – a highly significant difference.
By any clinical measure, these are meaningful results that translate into real improvements in cardiovascular risk, joint health, and metabolic function.
For context, the injectable form of Wegovy produces slightly higher average weight loss – around 14.9% in comparable trials.
That small gap matters in some clinical discussions, but in practical terms, the majority of patients on either treatment will achieve substantial and sustained weight reduction.
Pill vs. Injection: A Practical Comparison
The approval of the Wegovy pill does not render the injection obsolete. The two formulations have distinct profiles, and the right choice depends on individual circumstances, preferences, and clinical factors.
Here is how they compare.
Convenience and Lifestyle
This is where the pill holds a clear advantage. The Wegovy injection must be refrigerated – stored between 2°C and 8°C – after opening.
For patients who travel regularly, this presents a logistical challenge: keeping medication cold on long-haul flights, business trips, or holidays abroad requires planning and, often, a letter from a prescriber for airport security.
The pill, by contrast, can be stored at room temperature. It fits in a handbag, a travel wash bag, or a desk drawer.
There is no cold chain to manage, no fridge dependency, and crucially, no sharps disposal.
Patients taking the injection are required to dispose of used needles safely in an approved sharps container – a requirement that, while manageable at home, can feel cumbersome day to day and particularly awkward when travelling or staying away from home.
For needle-averse patients, the psychological advantage of the pill is equally significant.
A meaningful proportion of people who would benefit from GLP-1 treatment have delayed or declined it specifically because of a fear of self-injection.
The arrival of an oral alternative removes that barrier entirely.
Dosing Frequency
Here the injection has the edge.
Wegovy injections are administered just once a week – a dose schedule that is easy to build into a routine and easy to forget about between doses.
There are no daily reminders, no morning rituals, and no restrictions on when you eat.
The pill, by contrast, is taken once daily and comes with specific requirements: it must be swallowed first thing in the morning, on an empty stomach, with no more than 120 ml (around half a cup) of plain water.
You must then wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications.
This is because the pill uses a specialised absorption-enhancing agent called SNAC (salcaprozate sodium) to help semaglutide pass through the stomach lining – a process sensitive to food and competing substances.
For patients who are already disciplined about morning routines, this is unlikely to be a significant hurdle.
For those with irregular schedules or who take other morning medications, it is worth discussing with your pharmacist or prescriber before switching.
Absorption and Bioavailability
The science here is worth understanding.
When semaglutide is injected subcutaneously (under the skin), it is absorbed with approximately 89% bioavailability – meaning the vast majority of the active compound reaches the bloodstream intact.
In tablet form, oral bioavailability of semaglutide is considerably lower, around 1–2%, which is why the oral dose is substantially higher than the injectable equivalent.
The SNAC compound helps compensate for this, facilitating absorption across the gastric mucosa, but the inherent pharmacokinetic difference is why the injection retains a modest edge in average efficacy.
This also explains why some patients experience more belching with the oral form – a reported side effect in around 14% of pill users, compared with negligible rates among injection users.
Who Might Benefit Most from the Pill?
The Wegovy pill is likely to be particularly well suited to:
- Patients with a needle phobia or significant anxiety around injections
- Frequent travellers who find refrigeration impractical
- Those who prefer a discreet, portable daily tablet over a weekly injection
- Patients currently considering GLP-1 treatment but deterred by the administration route
The injection may remain preferable for patients who value the once-weekly schedule, have struggled with daily oral medication adherence in the past, or where clinical evidence suggests the marginally higher average weight loss is a relevant factor.
What Happens Next?
The MHRA approval, granted on 11 June 2026, marks the regulatory green light – but the Wegovy pill is not yet commercially available in the UK.
Novo Nordisk, the manufacturer, has indicated plans to launch in select markets in the second half of 2026.
At McMinn’s Pharmacy, we are monitoring supply availability closely and will be stocking the pill as soon as it becomes available.
If you are interested in finding out whether the Wegovy pill or injection might be appropriate for you, speak to one of our pharmacists.
We can provide guidance on eligibility, discuss the differences between formulations in the context of your individual health and lifestyle, and ensure you are supported throughout your treatment.
Medicated weight loss is evolving rapidly. The arrival of an oral GLP-1 treatment represents a genuine step forward in accessibility – and we are here to help you navigate it.
McMinn’s Pharmacy provides weight management consultations and stocks a range of clinically approved treatments. Speak to our team for personalised advice.